Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 6/20 | 0.49 |
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795019 | 0.90 | KDR (0.52) | MAPTKDRABL1SMOTRPV1 | |
| SCHEMBL6793327 | 0.90 | SMO (0.59) | KDRSMOTRPV1POLBGAA | |
| SCHEMBL6794939 | 0.90 | HTR2C (0.48) | MAPTKDRABL1SMOTRPV1 | |
| SCHEMBL6788429 | 0.87 | KDR (0.52) | MAPTKDRABL1SMOTRPV1 | |
| SCHEMBL6796259 | 0.84 | NPC1 (0.50) | MAPTSMOPOLBGAAMEN1 | |
| SCHEMBL6906387 | 0.84 | SMO (0.50) | MAPTSMOTRPV1POLBGAA | |
| SCHEMBL6800581 | 0.84 | MAPT (0.46) | MAPTKDRABL1SMOTRPV1 | |
| SCHEMBL6793936 | 0.82 | NPC1 (0.53) | MAPTSMOPOLBGAAMEN1 | |
| SCHEMBL6793719 | 0.82 | SMO (0.49) | MAPTSMOTRPV1POLBGAA | |
| SCHEMBL6794367 | 0.82 | SMO (0.48) | MAPTKDRABL1SMOTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MAPT 4795/4885KDR 3180/4885ABL1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.